1. Home
  2. MIRM vs AGYS Comparison

MIRM vs AGYS Comparison

Compare MIRM & AGYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • AGYS
  • Stock Information
  • Founded
  • MIRM 2018
  • AGYS 1963
  • Country
  • MIRM United States
  • AGYS United States
  • Employees
  • MIRM N/A
  • AGYS N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • AGYS EDP Services
  • Sector
  • MIRM Health Care
  • AGYS Technology
  • Exchange
  • MIRM Nasdaq
  • AGYS Nasdaq
  • Market Cap
  • MIRM 3.3B
  • AGYS 3.2B
  • IPO Year
  • MIRM 2019
  • AGYS N/A
  • Fundamental
  • Price
  • MIRM $76.06
  • AGYS $110.56
  • Analyst Decision
  • MIRM Strong Buy
  • AGYS Strong Buy
  • Analyst Count
  • MIRM 9
  • AGYS 5
  • Target Price
  • MIRM $73.89
  • AGYS $131.20
  • AVG Volume (30 Days)
  • MIRM 914.8K
  • AGYS 166.3K
  • Earning Date
  • MIRM 08-06-2025
  • AGYS 10-27-2025
  • Dividend Yield
  • MIRM N/A
  • AGYS N/A
  • EPS Growth
  • MIRM N/A
  • AGYS N/A
  • EPS
  • MIRM N/A
  • AGYS 0.49
  • Revenue
  • MIRM $429,161,000.00
  • AGYS $288,787,000.00
  • Revenue This Year
  • MIRM $52.71
  • AGYS $15.00
  • Revenue Next Year
  • MIRM $19.71
  • AGYS $17.48
  • P/E Ratio
  • MIRM N/A
  • AGYS $225.06
  • Revenue Growth
  • MIRM 62.33
  • AGYS 17.91
  • 52 Week Low
  • MIRM $36.86
  • AGYS $63.71
  • 52 Week High
  • MIRM $76.40
  • AGYS $142.64
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 77.75
  • AGYS 52.37
  • Support Level
  • MIRM $73.12
  • AGYS $104.32
  • Resistance Level
  • MIRM $76.02
  • AGYS $111.37
  • Average True Range (ATR)
  • MIRM 2.39
  • AGYS 2.77
  • MACD
  • MIRM 0.04
  • AGYS 0.29
  • Stochastic Oscillator
  • MIRM 96.66
  • AGYS 84.17

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About AGYS Agilysys Inc.

Agilysys Inc provides hospitality software delivering cloud-native SaaS and on-premise solutions for hotels, resorts, cruise lines, casinos, corporate foodservice management, restaurants, universities, stadiums, and healthcare facilities. The company's software solutions include point-of-sale (POS), property management (PMS), inventory and procurement, payments, and related applications that manage and enhance the entire guest journey. It derives maximum revenue from the provision of software subscription and maintenance services, followed by the provision of professional services, and the sale of products (proprietary software licenses, third-party hardware, and operating systems). Agilysys operates across North America, Europe, the Middle East, Asia-Pacific, and India.

Share on Social Networks: